Drug Discovery Case Studies (ME:200.707)
“Drug Discovery Case Studies” is designed to provide students with insights into the ever-changing landscape of drug discovery research by presenting case studies for various breakthrough drugs discovered since the 1940s. Each lecture selects a particular drug that has made a significant impact on patients’ lives and examines some key elements that have contributed to its successful discovery and development. The course is given by the lecturers that participated in “Introduction to Drug Discovery Research”. The final three lectures will be given by guest speakers who will present case studies on new drugs in which they were directly involved at the time of discovery and development.
Fall 2022
Course Director: Takashi Tsukamoto (ttsukamoto@jhmi.edu)
Location: Rangos 590
Time: 10:00 AM – 11:30 AM
Dates: Every Friday 9/9/2022-12/16/2022
Prerequisite:
No prior knowledge in drug discovery is required. This course is recommended for students in the 2nd or later year of their graduate program.
Grades will be determined by:
(i) class participation (25%); (ii) group project (50%) where 5-6 students will form a team to prepare a case study presentation; (iii) critique paper (25%) on one of the two other students’ presentations.
All students with disabilities who require accommodations for this course should contact Catherine L. Will, Disability Services Coordinator for Graduate Biomedical Education (cwill@jhmi.edu or 410-614-3781) at their earliest convenience to discuss their specific needs. Please note that accommodations are not retroactive.
Course Schedule
|
Topic |
Lecturer |
9/9 |
Introduction |
Takashi Tsukamoto |
9/16 |
Penicillin |
Takashi Tsukamoto |
9/23 |
Methotrexate |
Kathryn Lemberg |
9/30 |
Propranolol |
Jim Barrow |
10/7 |
Captopril |
David Meyers |
10/14 |
Omeprazole |
Diane Peters |
10/21 |
Aripiprazole |
Takashi Tsukamoto |
10/28 |
Tixagevimab/Cilgavimab (Evusheld®) |
Mark Esser (AstraZeneca) |
11/4 |
Nirmatrelvir/Ritonavir (Paxlovid®) |
Claire Steppan (Pfizer) |
11/11 |
Risdiplam (Evrysdi®) |
Alexander Stephan (Roche) |
11/18 |
Group Discussion |
|
12/2 |
Case Study Presentation 1 |
Students |
12/9 |
Case Study Presentation 2 |
Students |
12/16 |
Case Study Presentation 3 |
Students |
|
|
|
|
|
|
|
|
|
Past Guest Lectures
|
Topic |
Lecturer |
10/31/12 |
Eribulin |
Bruce Littlefield (Eisai)* |
11/7/12 |
Denosumab |
Scott Simonet (Amgen)* |
11/14/12 |
Raltegravir |
Steve Young (formerly at Merck)* |
10/29/14 |
Tafacitinib |
Chakrapani Subramanyam (Pfizer) |
11/5/14 |
Trastuzumab emtansine |
Gail Phillips (Genentech) |
11/12/14 |
Linaclotide |
Caroline Kurtz (Ironwood Pharma) |
10/28/16 |
Ledipasvir/Sofosbuvir (Harvoni®) |
Michael Sofia (Arbutus Biopharma, Inc.) |
11/4/16 |
Mepolizumab (Nucala®) |
Steven Yancey (GlaxoSmithKline) |
11/11/16 |
Lumacaftor/Ivacaftor (Orkambi®) |
Mark Miller (Vertex Pharmaceuticals Inc.) |
10/19/18 |
Etelcalcetide (Parsabiv®) |
Les Miranda (Amgen) |
11/2/18 |
Durvalumab (Imfinzi®) |
Scott Hammond (MedImmune) |
11/9/18 |
Suvorexant (Belsomra®) |
Anthony Roecker (Merck) |
10/30/20 |
Erenumab (Aimovig®) |
Cen Xu (Amgen) |
11/6/20 |
Elexacaftor/ivacaftor/tezacaftor (Trikafta®) |
Mark Miller (Vertex Pharmaceuticals) |
11/13/20 |
Ivosidenib (Tibsovo®) |
Zenon Konteatis (Agios Pharmaceuticals) |
|
|
|
|
|
|